Sage Therapeutics Inc (NASDAQ: SAGE) stock closed at $19.29 on 11/14/23 after a major increase of 11.4%. The stock has declined -6.4% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, SAGE is expected to continue to be Value Creation neutral.
Sage Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Sage Therapeutics has a neutral Appreciation Score of 42 but a very low Power Rating of 13, leading to the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment